These findings were consistent with the analysis of SLC25A21 expression in AML patients, suggesting that the overexpression of SLC25A21 in AML may serve as a potential tumor-suppressing factor by inhibiting cell proliferation, facilitating cell apoptosis, and inducing cell cycle arrest. Here, SLC25A21 is linked to acute myeloid leukemia.